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186 Omalizumab in the treatment of ABPA in 32 patients with cystic
ﬁbrosis
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Objectives: ABPA (Allergic bronchopulmonary aspergillosis) affects up to 15%
of patients with cystic ﬁbrosis (CF). The treatment of this disease, except cortico-
steroid, remains debated. Only a few clinical cases of omalizumab treatment have
been reported in this disease.
Methods: This retrospective multicenter observational french study includes 32 pa-
tients (15 childrens and 17 adults) with cystic ﬁbrosis treated with omalizumab
for more than three months in the context of ABPA. Clinical characteristics,
concomitant medications (inhaled and oral corticosteroids, antifungal), changes in
lung function, BMI, serum IgE, side effects, previous treatments and the cost of
treatment were collected from patients, one year before the start of treatment and
during the ﬁrst year of treatment.
Results: No signiﬁcant differences could be demonstrated with regard to lung
function, BMI, or the number of patients receiving oral corticosteroids. At the time
of initiation of omalizumab, 59% of patients received oral corticosteroids versus
30% after one year of treatment. 78% of patients had received antifungal therapy at
the time of the introduction of omalizumab. Treatment tolerance was good (19% of
patients experience side effects). The total average cost of treatment was 3456.70
euros per patient per month.
Conclusion: Limitations of this retrospective study concerns the number of patients
with a wide disparity of use between different centers. In addition, the cost of this
treatment is high. In view of these results, it seems necessary to conduct prospective
studies to determine potential indications for omalizumab in patients with CF with
an ABPA.
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Objectives: Examine whether FEV1 and FEV1/FVC percent predicted values
in cystic ﬁbrosis (CF) patients (pts) differ between the classical used Knudson
equations and those proposed by the Global Lungs Initiative (GLI).
Methods: We used data from a group of paediatric pts from a CF Clinic at a
tertiary Hospital. Information extracted from lung function (LF) database: age,
sex, height, weight, FEV1 and FEV1/FVC (in L) and percent predicted values
according to Knudson equations (%K). One observation per patient was included.
LF was obtained and classiﬁed according ATS/ERS guidelines [Jaeger Masterscreen
Body Plethysmograph (Viasys Healthcare, GermanyV.5.22.1)]. The absolute values
were automatically analysed through the GLI_Sheet Calculator and the new values
registered as %GLI. Pts were assigned in groups according to age (5−12 and
13−18 yrs) and LF severity. Statistical analysis: Paired-sample T Test.
Results: 44 pts [(21 (52.3%) male; median age: 12 (5−18) years].
Knudson vs GLI results
Knudson GLI p value
FEV1 (Mean, SD) 85.1 (21.7) 76.6 (24.5) 0.00
FEV1/FVC (Mean, SD) 78.9 (11.0) 78.9 (11.0) 0.676
Signiﬁcant difference for mean percent predicted FEV1 according to the reference
equations used was found (p = 0.00), even when subgroups by age and severity were
tested. There was no difference forFEV1/FVC (p = 0.485). For 9 pts LF severity
changed after reanalysis, 5 from mild to moderate and 4 from moderate to moderate-
severe.
Conclusion: Our study shows that signiﬁcant differences exist depending on the
reference equations used. This may induce misclassiﬁcation of severity of LF in
CF patients, impact is yet to be determined.
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Rationale: Ineb AAD records information about the use of the device. It’s authorized for admin-
istration of colistimethate sodium (CMS) in CF patients (Promixin®, Proﬁle, UK). The main aim
of the study was to describe the adherence to the inhaled antibiotic treatment and lung function in
CF patients.
Methods: Retrospective study carried out at 10 CF Spanish centers. Patients with CF colonized
with Pseudomonas aeruginosa (PA), in treatment with CMS with Ineb for at least 12 months, were
included. At baseline, lung function, anthropometric data and long-term treatments were recorded.
During 12 months, health outcomes and treatments were obtained from medical records by quarters.
Information about Ineb use was downloaded to calculate adherence to the treatment. ANCOVA was
performed to compare mean differences.
Results: Data from 108 patients with CF were analyzed (mean age: 24.5±10.2 years; range: 4−57;
38.9% female). Mean inhaled antibiotic adherence was 65.9±34.7%. Table shows association between
four measures of adherence and the %FEV1 predicted at baseline and the change in %FEV1 predicted
in 12 months adjusted for %FEV1 predicted at 1st quarter.
Association between adherence and FEV1
Adherence True adherence % days Ineb was used
at least once
% days Ineb was used
at least twice
%FEV1 pred Baseline p = 0.0037 p = 0.0050 p = 0.0012 p = 0.0003
Dif %FEV1 pred in 12 months
(adjusted for %FEV1 pred in
1st quarter)
p = 0.30 p = 0.37 p = 0.29 p = 0.072
Conclusions: In this population of CF patients we ﬁnd an association between adherence to the
inhaled antibiotic treatment and the %FEV1 predicted at baseline but not at 12 months. Only the
association with the % of days the Ineb was used at least twice tends to statistical signiﬁcance.
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Objectives: To identify nocturnal hypoxemia (NH) in CF children and to determine
if spirometry is a good predictor.
Methods: Twenty-ﬁve stable patients (pts) underwent a sleep questionnaire (SQ)
and an overnight pulse oximetry (OPO). Oxygen dessaturation index (ODI) was
classiﬁed as mild 3/h, moderate 6/h or severe 10/h. Correlation with spirom-
etry was performed. Values are presented as percent predicted (FEV1, FVC,
FEV1/FVC ratio and FEF25−75). Statistical analysis: linear regression and c2.
Results: Twelve (48%) male pts; median age 13 (7−18) years. Mean ODI was
4.5/h (13 normal, 6 mild, 3 moderate and 3 severe). Spirometry was normal in
6 pts (normal ODI in 3).
Table: ODI/Spirometry results
ODIMean
(SD)/n
patients
FVC Mean
(SD)
FEV1
Mean (SD)
FEV1/FVC
Mean (SD)
FEF25−75
Mean (SD)
4.8 (0.45)/6 101.4 (17.53) 95.4 (24.1) 81.1 (11.81) 63.8 (33.8)
7.9 (1.53)/3 88.4 (14.31) 82.0 (21.2) 77.9 (8.9) 43 (24.5)
15.4 (5.06)/3 84.5 (28.80) 79.0 (28.1) 79.1 (6.11) 34.2 (21.6)
No correlation was found between OPO and spirometry values. However, subgroup
analysis showed correlation between moderate ODI and all spirometry values
(R2 > 0.90) and severe ODI and FEV1/FVC and FEF25−75 (r
2 = 0.957/r2 = 0.668).
Respiratory disturbed sleep arose from SQ in 50% of pts but no correlation was
found with ODI severity.
Conclusions: This study shows that oxygen dessaturation during sleep is common
in paediatric CF patients. At least for moderate or severe disease spirometry may
be a better predictor of NO than history alone. Cut off spirometry values for OPO
studies must be determined.
